May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?

We read with interest the recent study by van Vugtet al.1whichadds data to the debate on a desirable improvement in thepolicy for the optimization of the organ allocation criteria inliver transplant (LT) setting.The aim of this multicenter registry based European studywas initially to investigate whether sarcopenia is a risk factor,independent of the model for end-stage liver disease (MELD)score, for waiting list mortality